Bio-Thera And Pharmapark Add Cosentyx Rival To Russia-CIS Collaboration
Secukinumab Biosimilar Expands Deal That Already Includes Golimumab And Ustekinumab
• By David Wallace
Bio-Thera and Pharmapark have expanded their collaboration in Russia and the CIS • Source: Shutterstock 
